Immunomodulators in Mechanically Ventilated Patients With COVID-19: Lessons Learned From Underpowered Trials.

Accessed August 20, 2022 7 COVID-19 Treatment Guidelines Panel: Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. COVID-19 patients with severe hypoxemia leading to acute respiratory distress syndrome (ARDS) requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO) experience disproportionately high mortality. * Keywords: acute respiratory distress syndrome; baricitinib; clinical trials; COVID-19; ruxolitinib EN acute respiratory distress syndrome baricitinib clinical trials COVID-19 ruxolitinib 1821 1828 8 11/21/22 20221201 NES 221201 Despite remarkable advances in supportive care, antiviral, and immunomodulatory therapies through rigorous clinical trials ([1]), patients with severe COVID-19 continue facing high burden of complications, including prolonged cognitive and physical sequelae, hospitalization, and risk of death. [Extracted from the article]